查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2013018

大腸直腸癌治療市場：2026年至2032年全球市場預測（依藥物類別、通路、給藥途徑、治療階段、標靶分子及治療環境分類）

Colorectal Cancer Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Line Of Therapy, Target Molecule, Treatment Setting - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，大腸直腸癌治療市場價值將達到 119.9 億美元，到 2026 年將成長至 126.6 億美元，到 2032 年將達到 195.7 億美元，複合年成長率為 7.24%。

主要市場統計數據
基準年 2025 119.9億美元
預計年份：2026年 126.6億美元
預測年份：2032年 195.7億美元
複合年成長率 (%) 7.24%

對複雜的結直腸癌藥物生態系統進行簡要概述，重點關注精準醫療、獲取趨勢和具有戰略意義的重要領域。

在快速發展的科學知識和不斷擴大的治療選擇的推動下，結直腸癌仍然是腫瘤學領域臨床上最複雜、商業性的領域之一。本執行摘要整合了塑造治療模式的臨床、監管和商業性趨勢，重點在於標靶治療、免疫腫瘤學和聯合治療的創新如何重新定義標準治療。引言部分從兩個觀點闡述了當前情況：以患者為中心的治療結果以及開發商、支付方和醫療服務提供者面臨的戰略挑戰，重點關注基於生物標記的治療選擇與日益精細的安全性和有效性評估之間的相互作用。

分子層級分層、新型治療方法和不斷發展的給藥模式如何重塑大腸直腸癌治療的臨床路徑和商業性重點？

大腸直腸癌的治療格局正在經歷一場變革，這主要得益於分子標靶治療、免疫調節和遞送技術的突破性進展。在臨床層面，基於生物標記的分層技術的成熟使得治療方法能夠更精準地應用於特定分子亞群，例如針對EGFR標靶藥物和針對錯配修復缺陷型腫瘤的免疫查核點抑制劑。同時，諸如過繼性細胞療法和基因修飾生技藥品等新型治療方法正從早期臨床開發階段邁向探索性聯合治療，旨在克服原發性和後天性抗藥性機制。這些進展拓展了個人化治療方案的選擇範圍，同時也增加了治療方法的複雜性，並促使人們對臨床路徑進行重新評估。

美國近期關稅措施對藥品供應鏈、籌資策略以及癌症治療取得管道的影響。

2025年實施的最新貿易和關稅措施進一步加劇了全球藥品供應鏈的複雜性，對癌症治療藥物的採購、定價策略和跨境分銷產生了切實的影響。為此，生產商和經銷商正在重新審視其原料藥和成品的籌資策略，力求透過本地化生產、供應來源多元化和重新談判物流合約來降低關稅成本。對於依賴緊密相連的全球供應鏈的注射用生物製藥和複雜的小分子原料而言，這些營運調整尤其顯著。

我們從涵蓋治療領域、分銷管道、給藥途徑和分子標靶的綜合細分觀點製定臨床和商業策略。

細分市場層面的趨勢揭示了清晰的臨床和營運重點，這些重點指南著跨治療領域、分銷管道、給藥途徑、治療線、目標分子和治療環境的產品定位、臨床實驗室設計和商業化策略。從藥物類別來看，化療仍然至關重要，Fluoropyrimidines、含鉑類藥物和拓樸異構酶抑制劑仍然是許多治療方案的標準框架。同時，免疫療法正透過查核點抑制劑和過繼性細胞療法不斷發展，這些療法旨在增強免疫反應並延長療效。單株抗體策略著重於表皮生長因子受體抑制劑和血管內皮生長因子抑制劑，從而實現標靶細胞外抑制；而小分子抑制劑則強調透過BRAF抑制劑、MEK抑制劑和蛋白酪氨酸激酶抑制劑來調控細胞內訊號傳導，這些抑制劑針對特定的癌基因驅動因子。

全球主要地區在監管、支付方和基礎設施方面的差異如何影響大腸癌治療的取得管道和部署模式？

區域趨勢差異顯著，影響美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式、監管重點和商業性准入策略。在美洲，監管創新和成熟的精準腫瘤學基礎設施推動了生物標記主導療法的快速普及。同時，支付方的嚴格審查和估值框架也促進了強力的證據整合和受控的市場准入方案。這種區域環境有利於那些能夠提供與真實臨床結果相關的、具有明顯差異化療效和可操作准入管道的研發者。

競爭格局的變化趨勢是由整合藥物開發、伴隨診斷以及不同相關人員的。

大腸直腸癌領域的競爭格局呈現出多元化的特徵，包括大型跨國製藥公司、專注於腫瘤生物技術的公司、診斷研發企業以及合約服務供應商，它們各自為治療方法的推進和商業化貢獻著獨特的優勢。大型製藥企業利用其龐大的研發資源和全球商業化網路，支持後期研發計畫和多區域上市，通常透過將新型藥物與成熟的化療方案結合，以實現療效的提升。專注於細胞治療方法和高選擇性激酶抑制劑等細分領域的生物技術公司則致力於推動創新，透過快速迭代、以生物標記主導的檢測設計以及策略夥伴關係，加速臨床概念驗證。

製藥和生物技術領導者採取策略行動，協調創新、供應鏈韌性和以支付方為中心的證據生成，以實現永續的治療成功

針對行業領導者的實用建議著重於將臨床創新與切實可行的准入管道和業務永續營運結合，以應對不斷變化的結直腸癌治療格局。首先，應優先與監管機構和支付相關人員進行早期且持續的合作，制定涵蓋臨床療效和真實世界療效的實證方案，確保關鍵臨床試驗包含與決策者相關的終點和亞群。其次，應投資開發伴隨診斷，並與治療方案同步進行，以確保及時識別患者，並透過精準醫療提升治療價值。

採用嚴謹的多方面研究途徑，結合臨床文獻、監管趨勢、專家意見和真實世界數據，對治療和獲取方面的趨勢進行背景分析。

本執行摘要的研究整合了同行評審的臨床文獻、監管指導文件、已發表的臨床實驗室結果、企業科學通訊以及公開的治療指南，旨在構建整體情況且平衡的結直腸癌治療現狀圖景。重點在於將關鍵實驗室檢測報告的臨床結果與後續的真實世界分析結果進行交叉比對（如有），從而能夠在受控實驗室環境之外對轉化應用效果進行實際評估。此外，也透過分析近期核准通知、附加檔更新以及已發布的諮詢委員會審議記錄，探討監管趨勢，以了解不斷變化的證據要求。

將臨床創新與營運挑戰結合，強調綜合證據、診斷一致性和穩健的准入策略。

總之，大腸直腸癌的治療格局正在迅速轉變，分子標靶療法、不斷擴展的免疫療法以及不斷演進的給藥模式，全面提升了精準醫療的潛力。然而，這些科學進步也伴隨著許多實際挑戰，例如供應鏈的韌性、支付者的期望以及在不同醫療機構中實施複雜治療方法所帶來的營運需求。因此，要實現永續的臨床和商業性成功，需要製定一項整合策略，將差異化證據的產生、切實可行的准入方案以及穩健的營運計劃相結合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：大腸直腸癌治療市場：依藥物類別分類

  • 化療
    • Fluoropyrimidines
    • 含鉑類藥物
    • 拓樸異構酶抑制劑
  • 免疫療法
    • 過繼性細胞療法
    • 查核點抑制劑
  • 單株抗體
    • 表皮生長因子受體抑制劑
    • 血管內皮生長因子抑制劑
  • 小分子抑制劑
    • BRAF抑制劑
    • MEK抑制劑
    • 蛋白酪氨酸激酶抑制劑

第9章：大腸直腸癌治療藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章：大腸直腸癌治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第11章：大腸直腸癌治療市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 第三行

第12章：大腸直腸癌治療市場：以標靶分子分類

  • 表皮生長因子受體
  • 程序性細胞死亡蛋白1
  • 程序性細胞死亡配體1
  • 血管內皮生長因子

第13章：大腸直腸癌治療市場：依治療環境分類

  • 住院治療
  • 門診

第14章：大腸直腸癌治療藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：大腸直腸癌治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：大腸直腸癌治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國大腸直腸癌治療市場

第18章：中國大腸直腸癌治療藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accord Healthcare Limited（Intas Pharmaceuticals Ltd.）
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • HUTCHMED (China) Limited
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Manus Aktteva Biopharma LLP
  • Marksans Pharma Ltd.
  • Merck & Co., Inc.
  • Mylan NV（Viatris Inc.）
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Taiho Pharmaceutical Co., Ltd.（Otsuka Pharmaceutical Co., Ltd.）
  • Takeda Pharmaceutical Company Limited
  • VolitionRx Limited
Product Code: MRR-431B7BFFBF56

The Colorectal Cancer Drugs Market was valued at USD 11.99 billion in 2025 and is projected to grow to USD 12.66 billion in 2026, with a CAGR of 7.24%, reaching USD 19.57 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.99 billion
Estimated Year [2026] USD 12.66 billion
Forecast Year [2032] USD 19.57 billion
CAGR (%) 7.24%

A concise orientation to the complex colorectal cancer treatment ecosystem highlighting precision therapeutics, access dynamics, and strategic focus areas

Colorectal cancer remains one of the most clinically complex and commercially dynamic oncology areas, driven by rapidly evolving scientific understanding and a widening therapeutic toolbox. This executive summary synthesizes clinical, regulatory, and commercial developments shaping treatment paradigms, with particular attention to how innovation in targeted agents, immuno-oncology, and combination regimens is redefining standards of care. The introduction positions the landscape through the dual lenses of patient-centric outcomes and strategic imperatives for developers, payers, and providers, highlighting the interplay between biomarker-driven treatment selection and an increasingly nuanced safety-efficacy calculus.

As diagnostic capabilities advance and precision medicine becomes more embedded in practice, the continuum of care for colorectal cancer is shifting from one-size-fits-all cytotoxic regimens to more individualized approaches. This transition generates new opportunities for clinical differentiation and commercial value capture, while also demanding tighter alignment across clinical development, real-world evidence generation, and payer engagement. The introduction closes by outlining the scope of the analysis and the principal thematic threads that recur throughout the report: innovation, access, cost-management pressures, and the operational challenges of bringing complex regimens to heterogeneous health systems.

How molecular stratification, novel modalities, and evolving delivery models are reshaping clinical pathways and commercial priorities in colorectal therapeutics

The therapeutic landscape for colorectal cancer is experiencing transformative shifts driven by breakthroughs in molecular targeting, immune modulation, and delivery technologies. At the clinical level, the maturation of biomarker stratification is enabling more precise use of therapies such as EGFR-directed agents for defined molecular cohorts and immune checkpoint inhibitors for mismatch repair-deficient tumors. Concurrently, novel modalities including adoptive cell therapies and engineered biologics are progressing from early clinical development into exploratory combinations that aim to overcome primary and acquired resistance mechanisms. These developments are reshaping clinical pathways by expanding options for personalized sequences of care while also increasing regimen complexity.

From a commercial perspective, payers and providers are recalibrating procurement and reimbursement approaches to accommodate high-cost specialty agents alongside conventional chemotherapy backbones. Real-world evidence initiatives and managed entry agreements are becoming more prevalent as stakeholders seek to balance rapid patient access with evidence generation post-launch. Furthermore, the proliferation of oral targeted therapies and subcutaneous biologics is influencing distribution and adherence strategies, prompting shifts in how institutions and outpatient settings manage therapy delivery. Collectively, these dynamics are creating new competitive dimensions that reward developers who can demonstrate differentiated clinical value, pragmatic delivery models, and robust evidence of sustained benefit in routine practice.

Implications of recent United States tariff measures on pharmaceutical supply chains, procurement strategies, and access pathways for oncology therapies

Recent trade and tariff policies implemented within the United States in 2025 introduced incremental complexity to global pharmaceutical supply chains, with tangible implications for procurement, pricing strategies, and cross-border distribution of oncology therapeutics. Manufacturers and distributors have responded by re-evaluating sourcing strategies for active pharmaceutical ingredients and finished products, seeking to mitigate tariff-driven cost exposure through localized manufacturing, supply diversification, and renegotiated logistics contracts. These operational adjustments are particularly salient for injectable biologics and complex small molecule inputs that depend on tightly coordinated global supply chains.

In parallel, health systems and pharmacy networks have had to adjust contracting approaches to preserve patient access while managing budgetary constraints. In some cases, purchasers accelerated multi-year agreements or explored value-based contracting structures to stabilize net costs and ensure continuity of supply. At the clinical level, formulary committees are placing greater emphasis on therapeutic interchange protocols and total cost of care considerations when evaluating new entries. The net effect is a heightened importance of supply chain resilience and commercial agility; companies that can demonstrably secure supply, hedge tariff exposure, and partner on innovative access mechanisms are better positioned to maintain competitive continuity during periods of trade policy uncertainty.

Integrated segmentation perspectives across therapeutic classes, distribution pathways, administration routes, and molecular targets to inform clinical and commercial strategies

Segment-level dynamics reveal distinct clinical and operational priorities that inform product positioning, trial design, and commercialization tactics across therapeutic classes, distribution channels, routes of administration, lines of therapy, target molecules, and treatment settings. By drug class, chemotherapy maintains foundational relevance with fluoropyrimidines, platinum compounds, and topoisomerase inhibitors continuing as standard backbones for many regimens, while immunotherapy expands through checkpoint inhibitors and adoptive cell therapies that target immune responsiveness and durable benefit. Monoclonal antibody strategies concentrate on epidermal growth factor receptor inhibitors and vascular endothelial growth factor inhibitors, delivering targeted extracellular blockade, whereas small molecule inhibitors emphasize intracellular signaling control via BRAF inhibitors, MEK inhibitors, and tyrosine kinase inhibitors that address specific oncogenic drivers.

Across distribution channels, hospital pharmacies remain central for inpatient infusions and complex combination protocols, while retail pharmacies and online specialty pharmacies increasingly support oral targeted agents and subcutaneous formulations to improve convenience and adherence. Route of administration continues to influence clinical workflow and patient preference: intravenous therapies dominate acute treatment settings, oral agents enable outpatient administration and home-based adherence models, and subcutaneous formulations create opportunities for clinic efficiency and patient comfort. Line of therapy segmentation shapes clinical evidence needs, with first-line approvals demanding demonstration of superior outcomes and tolerability, and second- or third-line positioning often emphasizing response in molecularly defined or refractory populations. From a target molecule perspective, focus areas include epidermal growth factor receptor, programmed cell death protein 1, programmed death ligand 1, and vascular endothelial growth factor, each of which informs companion diagnostics and combination strategies. Treatment setting considerations, differentiated between inpatient and outpatient contexts, affect resource allocation, dosing schedules, and provider training needs. Integrating these segmentation lenses enables developers and payers to align clinical value propositions with practical delivery considerations and to prioritize evidence generation that resonates across decision-makers.

How regional regulatory, payer, and infrastructure differences across major global regions shape access pathways and adoption patterns for colorectal treatments

Regional dynamics vary substantially, shaping clinical practice patterns, regulatory emphasis, and commercial access strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory innovation and established precision oncology infrastructure support rapid uptake of biomarker-driven therapies, while payer scrutiny and value frameworks incentivize robust evidence packages and managed entry solutions. This regional environment favors sponsors that present clear outcomes differentiation and pragmatic access pathways tied to real-world outcomes.

Across Europe, Middle East & Africa, the interplay between centralized regulatory guidance and diverse national reimbursement systems drives nuanced market entry tactics, where early health technology assessment engagement and pricing negotiations are critical. Capacity constraints in some markets also influence the adoption pace of complex modalities that require specialized delivery infrastructure. In the Asia-Pacific region, heterogeneity in regulatory timelines and expanding investments in oncology care are creating mixed adoption rhythms; certain markets demonstrate rapid embrace of oral targeted therapies and localized manufacturing investments, while others prioritize cost-effective interventions and scalable delivery models. Overall, regional strategies must balance localized payer expectations, infrastructure readiness, and partnership models that support sustainable access and evidence generation.

Competitive landscape dynamics driven by integrated drug development, companion diagnostics, and collaborative commercialization approaches among diverse stakeholders

Competitive dynamics in the colorectal cancer space reflect a blend of large multinational pharmaceutical companies, specialized oncology biotechs, diagnostic developers, and contract service providers, each contributing distinct capabilities to therapeutic advancement and commercialization. Large pharmaceutical organizations leverage expansive development resources and global commercialization networks to support late-stage programs and multi-region launches, often pairing novel agents with established chemotherapy backbones to demonstrate incremental benefit. Specialized biotechs drive innovation in niche modalities such as cell therapies and highly selective kinase inhibitors, focusing on rapid iteration, biomarker-driven trial designs, and strategic partnerships to accelerate clinical proof-of-concept.

Diagnostic developers are increasingly central to competitive positioning, supplying companion assays that enable targeted prescribing and enhance the clinical utility of precision agents. Meanwhile, contract development and manufacturing organizations, as well as specialty distribution partners, provide the operational backbone for complex biologics and novel formulations, supporting scale-up and flexible supply strategies. Collaboration patterns are shifting toward co-development and data-sharing arrangements that align clinical endpoints with payer-relevant outcomes, and companies that integrate diagnostics, streamlined manufacturing, and pragmatic evidence plans tend to achieve stronger uptake and sustained clinical differentiation.

Strategic actions for pharmaceutical and biotech leaders to align innovation, supply resilience, and payer-focused evidence generation for durable therapeutic success

Actionable recommendations for industry leaders focus on aligning clinical innovation with pragmatic access pathways and operational resilience to navigate the evolving colorectal oncology environment. First, prioritize early and iterative engagement with regulatory and payer stakeholders to design evidence-generation plans that address both clinical efficacy and real-world effectiveness, ensuring that pivotal trials include endpoints and subgroups relevant to decision-makers. Second, invest in companion diagnostic development alongside therapeutic programs to secure timely patient identification and to strengthen the value narrative through precision use.

Third, build supply chain flexibility through regional manufacturing options, strategic inventory buffers, and diversified sourcing of critical inputs to mitigate exposure to trade policy fluctuations and logistic disruptions. Fourth, design commercialization models that reflect route of administration and care setting, leveraging specialty pharmacy and outpatient delivery partnerships for oral and subcutaneous agents while maintaining hospital channel support for complex infusion regimens. Finally, pursue collaborative data initiatives and value-based contracting pilots to demonstrate outcomes and share risk with payers, thereby accelerating access while creating defensible differentiation based on measurable patient benefit.

A rigorous multi-source research approach combining clinical literature, regulatory updates, expert input, and real-world evidence to contextualize therapeutic and access dynamics

The research underpinning this executive summary synthesizes peer-reviewed clinical literature, regulatory guidance documents, published clinical trial results, company scientific communications, and publicly available treatment guidelines to construct a comprehensive and balanced view of the colorectal cancer therapeutic landscape. Emphasis was placed on cross-referencing clinical outcomes reported in pivotal studies with subsequent real-world analyses where available, enabling a pragmatic assessment of translational performance outside controlled trial settings. Regulatory trends were analyzed through recent approval letters, label updates, and public advisory committee deliberations to identify evolving evidentiary expectations.

Supplementary qualitative inputs were derived from expert physician commentary and payer policy statements to contextualize adoption enablers and barriers across different health systems. Supply chain and commercial access considerations were evaluated by examining manufacturing footprints, distribution channel evolution, and trade policy communications. Throughout, methodological rigor was maintained by triangulating multiple independent sources for key assertions, prioritizing primary data where possible, and transparently noting areas of ongoing clinical uncertainty that warrant targeted evidence generation.

Synthesis of clinical innovation and operational imperatives emphasizing integrated evidence, diagnostics alignment, and resilient access strategies

In conclusion, the colorectal cancer treatment landscape is undergoing rapid transformation driven by molecularly targeted therapies, expanding immunotherapy approaches, and evolving delivery models that collectively enhance the potential for more personalized care. These scientific advances, however, coexist with practical challenges related to supply chain resilience, payer expectations, and the operational demands of delivering complex regimens across diverse care settings. Achieving durable clinical and commercial success will therefore require integrated strategies that link differentiated evidence generation to pragmatic access solutions and robust operational planning.

Stakeholders who align product development with companion diagnostics, anticipate payer needs through outcome-focused evidence, and shore up supply and distribution agility will be best positioned to translate therapeutic innovation into sustained patient benefit. As the landscape continues to evolve, ongoing collaboration among developers, diagnostics providers, payers, and providers will be essential to convert scientific progress into accessible, effective care pathways for patients living with colorectal cancer.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Colorectal Cancer Drugs Market, by Drug Class

  • 8.1. Chemotherapy
    • 8.1.1. Fluoropyrimidines
    • 8.1.2. Platinum Compounds
    • 8.1.3. Topoisomerase Inhibitors
  • 8.2. Immunotherapy
    • 8.2.1. Adoptive Cell Therapies
    • 8.2.2. Checkpoint Inhibitors
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Epidermal Growth Factor Receptor Inhibitors
    • 8.3.2. Vascular Endothelial Growth Factor Inhibitors
  • 8.4. Small Molecule Inhibitors
    • 8.4.1. BRAF Inhibitors
    • 8.4.2. MEK Inhibitors
    • 8.4.3. Tyrosine Kinase Inhibitors

9. Colorectal Cancer Drugs Market, by Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies

10. Colorectal Cancer Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Colorectal Cancer Drugs Market, by Line Of Therapy

  • 11.1. First Line
  • 11.2. Second Line
  • 11.3. Third Line

12. Colorectal Cancer Drugs Market, by Target Molecule

  • 12.1. Epidermal Growth Factor Receptor
  • 12.2. Programmed Cell Death Protein 1
  • 12.3. Programmed Death Ligand 1
  • 12.4. Vascular Endothelial Growth Factor

13. Colorectal Cancer Drugs Market, by Treatment Setting

  • 13.1. Inpatient
  • 13.2. Outpatient

14. Colorectal Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Colorectal Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Colorectal Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Colorectal Cancer Drugs Market

18. China Colorectal Cancer Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
  • 19.6. Amgen Inc.
  • 19.7. Amneal Pharmaceuticals, Inc.
  • 19.8. Apotex Inc.
  • 19.9. Bayer AG
  • 19.10. Bristol-Myers Squibb Company
  • 19.11. Eisai Co., Ltd.
  • 19.12. Eli Lilly and Company
  • 19.13. F. Hoffmann-La Roche Ltd
  • 19.14. GlaxoSmithKline PLC
  • 19.15. HUTCHMED (China) Limited
  • 19.16. Lupin Limited
  • 19.17. Mallinckrodt Pharmaceuticals
  • 19.18. Manus Aktteva Biopharma LLP
  • 19.19. Marksans Pharma Ltd.
  • 19.20. Merck & Co., Inc.
  • 19.21. Mylan N.V. by Viatris Inc.
  • 19.22. Novartis AG
  • 19.23. Pfizer Inc.
  • 19.24. Regeneron Pharmaceuticals, Inc.
  • 19.25. Sanofi S.A.
  • 19.26. Sumitomo Pharma Co., Ltd.
  • 19.27. Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
  • 19.28. Takeda Pharmaceutical Company Limited
  • 19.29. VolitionRx Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY MEK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED DEATH LIGAND 1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 200. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 205. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 210. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 233. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 238. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 244. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 249. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)